Phase II Trial of Continuation Therapy in Advanced NSCLC

Conditions:Lung Cancer, Lung Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:March 20, 2017
End Date:December 2019
Contact:Donna Sullivan

Use our guide to learn which trials are right for you!

A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029

This is a single-arm phase II study of continuation immunotherapy with pembrolizumab
following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.

OUTLINE: This is a multi-center study.

Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3
months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of
each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every
three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine
1000mg/m2 IV D1 and D8 every three weeks, docetaxel 75mg/m2 IV D1 every three weeks, or
pemetrexed 500mg/m2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only).
Subjects will continue to receive this combination until progression or intolerable toxicity.

Administration Sequence: First Sequence

- Pembrolizumab 200mg IV on Day 1 (cycle = 21 days)

Administration Sequence: Second Sequence

- Gemcitabine 1000mg/m^2 IV on Days 1,8 (cycle = 21 days)

- Docetaxel 75mg/^2 IV on Days 1,8 (cycle = 21 days)

- Pemetrexed 500mg/m^2 IV on Day 1 (cycle -= 21 days)

Inclusion Criteria:

Subjects must meet all of the following applicable inclusion criteria to participate in
this study:

- Written informed consent and HIPAA authorization for release of protected health

- Age ≥ 18 years at the time of consent.

- Histological or cytological evidence of stage IV NSCLC (any histology)

- Subjects must have progressed on or after previous platinum-based chemotherapy.
Chemotherapy may have previously been given with a PD-1 or PD-L1 inhibitor. Subjects
must have also progressed on or after receiving any PD-1 or PD-L1 inhibitor (including
pembrolizumab) as their most recent therapy and must have had at least a 3-month PFS
on this therapy.

- Subjects must be enrolled on the trial within 6 weeks of their last infusion of PD-1
or PD-L1 inhibitor therapy.

- Subjects whose tumors harbor a mutation in EGFR exon 19 or 21 or have gene
rearrangements in ALK or ROS1 must have already been treated with standard targeted
therapies. NOTE: Subjects must also have progressed on or after platinum-containing
combination chemotherapy.

- ECOG Performance Status of 0 or 1 within 28 days prior to registration for protocol

- Must be fit enough to receive next-line chemotherapy (either gemcitabine, docetaxel,
or pemetrexed [non-squamous only]) according to the discretion of the treating

- Adequate laboratory values obtained within 28 days prior to registration for protocol

- Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy
test within 7 days prior to study registration and/or within 72 hours of first dose of
study drugs. If the urine test is positive or cannot be confirmed as negative, a serum
pregnancy test will be required.

- Women of childbearing potential must be willing to use two methods of contraception or
abstain from heterosexual activity from the point of registration through 120 days
after the last dose of study drug.

- Male subjects capable of fathering a child must agree to use an adequate method of
contraception starting with the first dose of the study drug through 120 days after
the last dose of the study drug.

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

- Pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 120 days after the last dose of trial treatment.

- Active central nervous system (CNS) metastases. NOTE: Subjects who are symptomatic or
have not undergone prior brain imaging must undergo a head computed tomography (CT)
scan or brain MRI within 28 days prior to registration to exclude brain metastases.

- Treatment with any investigational agent within 28 days prior to registration for
protocol therapy with the exception of PD-1 or PD-L1 inhibitors.

- No active second cancers with the exception of localized non-melanoma skin cancer,
in-situ cervical or in-situ bladder cancer.

- Evidence of active autoimmune disease requiring systemic treatment within the past 90
days or a documented history of clinically severe autoimmune disease, or a syndrome
that requires systemic steroids or immunosuppressive agents.

- History of (non-infectious) pneumonitis requiring treatment with corticosteroids,
evidence of interstitial lung disease or active, non-infectious pneumonitis.

- History of an immune-related toxicity requiring treatment with corticosteroids during
prior PD-1/ PD-L1 inhibitor treatment.

- Diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy
or other immunosuppressive therapy (excludes inhaled corticosteroids) within 7 days of
study registration.

- History of psychiatric illness or social situations that would limit compliance with
study requirements.

- Clinically active infection (≥ Grade 2) as judged by the site investigator.

- Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B
or C. NOTE: HIV, HBV or HCV testing is not required.

- History or current evidence of any condition, therapy, or laboratory abnormality that
might confound the results of the trial, interfere with the subject's participation
for the full duration of the trial, or is not in the best interest of the subject to
participate, in the opinion of the site investigator.

- Known history of active TB (Bacillus Tuberculosis).

- History of hypersensitivity to pembrolizumab, docetaxel, gemcitabine, pemetrexed or
any of their excipients.

- Has received a live vaccine within 30 days prior to planned start of study therapy.
We found this trial at
1801 West Taylor, Suite 1E
Chicago, Illinois 60612
Principal Investigator: Lawrence Feldman, MD
Phone: 312-355-4200
University of Illinois Cancer Center The University of Illinois Cancer Center is dedicated to reducing...
Chicago, IL
Click here to add this to my saved trials
535 Barnhill Dr
Indianapolis, Indiana 46202
(888) 600-4822
Phone: 317-656-4260
Indiana University Melvin and Bren Simon Cancer Center At the IU Simon Cancer Center, more...
Indianapolis, IN
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Muhammad Furgan, MD
Phone: 319-384-4241
Iowa City, IA
Click here to add this to my saved trials
Madison, Wisconsin 53792
(608) 263-2400
Principal Investigator: Ticiana Leal, MD
Phone: 608-263-3078
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
Madison, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Naomi Fujioka, MD
Minneapolis, MN
Click here to add this to my saved trials